Shares of the company, which also runs drugstores, rose 2.4% in
early trading.
CVS is moving deeper into healthcare and completed its Aetna
purchase last year, combining one of the largest pharmacy
benefit managers with one of the nation's oldest health
insurers.
The pharmacy benefits management (PBM) business, which
negotiates discounts with drugmakers for its clients that
include insurers, gained in the third quarter from increased
pharmacy claims and a rise in prices of branded drugs.
Sales in the unit rose 6.4% to $36.02 billion.
The healthcare benefits business, which houses Aetna, reported
sales of $17.18 billion, helped by lower-than-expected medical
costs.
The unit reported a medical benefit ratio of 83.3%, compared
with estimates of 84.3%, according to four analysts polled by
Refinitiv.
The ratio is a key metric that compares the amount CVS spent on
medical claims with income from premiums.
Even as the two businesses showed strength, CVS' retail unit
came under some pressure from lower reimbursement rates for
filing prescriptions, which has plagued the industry since the
past few quarters.
CVS's rival drugstore chain Walgreen Boots Alliance Inc <WBA.O>
has been exploring whether to go private following private
equity interest in the company, Reuters reported on Tuesday,
citing sources.
CVS said on Wednesday it plans to close 22 underperforming
retail pharmacy stores in the first quarter of 2020.
Sales in CVS's retail unit rose 2.9% to 21.47 billion, the
slowest growth rate across its businesses in the quarter.
The company now expects its 2019 adjusted profit to range
between $6.97 and $7.05 per share, compared with its previous
forecast of $6.89 to $7.00.
CVS's net profit rose 10.1% to $1.53 billion, or $1.17 per
share, in the quarter ended Sept. 30.
Excluding items, the company earned $1.84 per share, above
analysts' estimates of $1.77.
Revenue jumped 36.5% to $64.81 billion, beating the average
analyst estimate of $62.99 billion.
(Reporting by Manas Mishra and Trisha Roy in Bengaluru; Editing
by Maju Samuel)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|